Sugi Predict

Sugi Predict / Compounds / SCHEMBL29429843

SCHEMBL29429843

SCHEMBL29429843

Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.85

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 1/20 0.85
▸ NT5E P21589 1/20 0.80
▸ KRAS P01116 5/20 0.79
▸ FUT5 Q11128 1/20 0.78
▸ P2RX3 P56373 2/20 0.75
▸ P2RY2 P41231 3/20 0.71
▸ P2RY4 P51582 1/20 0.71
▸ P2RY6 Q15077 1/20 0.71
▸ DCPS Q96C86 1/20 0.68
▸ P2RY1 P47900 3/20 0.67
▸ SRC P12931 1/20 0.67
▸ P2RX1 P51575 1/20 0.67
▸ P2RX4 Q99571 1/20 0.67
▸ P2RX2 Q9UBL9 1/20 0.67
▸ ALDH1A1 P00352 1/20 0.67
▸ SMN1; SMN2 Q16637 1/20 0.67
▸ HINT1 P49773 1/20 0.66
▸ IMPDH2 P12268 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL851357 1.00 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
SCHEMBL18769114 1.00 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
SCHEMBL21067722 1.00 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL3333959 0.97 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL5809658 0.97 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL17367368 0.97 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL1304258 0.97 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL19691775 0.97 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL18784960 0.97 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL2593095 0.97 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622876-B2 Methods of suppressing delivery of exosomes to liver and spleen LONZA SALES AG (CH) 2026-05-12 — — US disclosed
EP-4731772-A1 CELL SPECIFIC TRANSLATION OF RNA MOLECULES SRTD biotech GmbH (DE) 2026-04-29 — — EP disclosed
US-12565666-B2 Methods and compositions for modulating a genome FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2026-03-03 — — US disclosed
EP-4684023-A2 MODIFIED TEMPLATE GUIDE RNA MOLECULES Tessera Therapeutics, Inc. (US) 2026-01-28 — — EP disclosed
EP-4680744-A2 SERPINA-MODULATING COMPOSITIONS AND METHODS Flagship Pioneering Innovations VI, LLC (US) 2026-01-21 — — EP disclosed
EP-4680737-A2 PAH-MODULATING SYSTEMS AND METHODS Flagship Pioneering Innovations VI, LLC (US) 2026-01-21 — — EP disclosed
WO-2025235506-A2 ATP7B-MODULATING COMPOSITIONS AND METHODS FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2025-11-13 — — WO disclosed
EP-4646479-A2 TRAC AND B2M MODULATING COMPOSITIONS AND METHODS Flagship Pioneering Innovations VI, LLC (US) 2025-11-12 — — EP disclosed
US-20250340907-A1 METHODS AND COMPOSITIONS FOR MODULATING A GENOME FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) 2025-11-06 — — US disclosed
US-20250312376-A1 COMPOSITIONS AND METHODS FOR MODULATING A GENOME IN T CELLS, INDUCED PLURIPOTENT STEM CELLS, AND RESPIRATORY EPITHELIAL CELLS FLAGSHIP PIONEERING INNOVATIONS VI, LLC 2025-10-09 — — US disclosed
EP-4114937-A2 METHODS AND COMPOSITIONS FOR MODULATING A GENOME Flagship Pioneering Innovations VI, LLC (US) 2023-01-11 — — EP disclosed
EP-4114940-A1 METHODS AND COMPOSITIONS FOR MODULATING A GENOME Flagship Pioneering Innovations VI, LLC (US) 2023-01-11 — — EP disclosed
EP-4114941-A2 IMPROVED METHODS AND COMPOSITIONS FOR MODULATING A GENOME Flagship Pioneering Innovations VI, LLC (US) 2023-01-11 — — EP disclosed
EP-4096682-A1 COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF Flagship Pioneering Innovations VI, LLC (US) 2022-12-07 — — EP disclosed
WO-2022198014-A1 LTR TRANSPOSON COMPOSITIONS AND METHODS FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2022-09-22 — — WO disclosed
CN-108473969-B Modification of RNA-associated enzymes for enhanced production 川斯勒佰尔公司 2022-09-13 — — CN disclosed
WO-2022173830-A1 NUCLEASE-GUIDED NON-LTR RETROTRANSPOSONS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2022-08-18 — — WO disclosed
CN-114686548-A Modification of RNA-associated enzymes for enhanced production 川斯勒佰尔公司 2022-07-01 — — CN disclosed
WO-2022122689-A1 RNA MANUFACTURING BioNTech SE (DE) 2022-06-16 — — WO disclosed
US-20220073875-A1 Amplifiable RNAs for Therapeutic Cell Systems RUBIUS THERAPEUTICS, INC. (US) 2022-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073875-A1 Amplifiable RNAs for Therapeutic Cell Systems NSUN3, RNGTT, NSUN2 TGM2 1436/4885NT5E 1045/4885KRAS 848/4885
US-12622876-B2 Methods of suppressing delivery of exosomes to liver and spleen EXOSC10, EXOSC5, EXOSC4 TGM2 2917/4885NT5E 2489/4885KRAS 350/4885
US-12565666-B2 Methods and compositions for modulating a genome RPRD2, ERN2, TPR TGM2 2000/4885NT5E 999/4885KRAS 4103/4885
US-20250312376-A1 COMPOSITIONS AND METHODS FOR MODULATING A GENOME IN T CELLS, INDUCED PLURIPOTENT STEM CELLS, AND RESPIRATORY EPITHELIAL CELLS CD74, CD4, MICA TGM2 1159/4885NT5E 950/4885KRAS 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.